ReviewFrontiers in pharmacology2020
Molecular Modeling Applied to the Discovery of New Lead Compounds for P2 Receptors Based on Natural Sources.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Modeling the P2X7 receptor: a comparative analysis of conventional methods and AlphaFold.Frontiers in pharmacology · 2026Article
- Investigating cannabinoids as P2X purinoreceptor 4 ligands by using surface plasmon resonance and computational docking.Heliyon · 2023Article
- Antihyperglycemic Potential ofJournal of clinical medicine · 2023Article
- Can Crude Oil Exploration Influence the Phytochemicals and Bioactivity of Medicinal Plants? A Case of NigerianMolecules (Basel, Switzerland) · 2022Article
- The Structural, Biological, and In-Silico Profiling of Novel Capryloyl Tetra-Glucoside and Aliphatic Ester Constituents from thePlants (Basel, Switzerland) · 2022Article
- Application of Mathematical Modeling and Computational Tools in the Modern Drug Design and Development Process.Molecules (Basel, Switzerland) · 2022Review
- Ameliorative Sexual Behavior and Phosphodiesterase-5 Inhibitory Effects ofJournal of clinical medicine · 2022Article
- Anti-Diabetic Activity of Bioactive Compound Extracted fromPlants (Basel, Switzerland) · 2022Article
- Challenges and advances in clinical applications of mesenchymal stromal cells.Journal of hematology & oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
P2 receptors are a family of transmembrane receptors activated by nucleotides and nucleosides. Two classes have been described in mammals, P2X and P2Y, which are implicated in various diseases. Currently, only P2Y12 has medicines approved for clinical use as antiplatelet agents and natural products have emerged as a source of new drugs with action on P2 receptors due to the diversity of chemical structures. In drug discovery,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.